Assembly Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY EPS (est.)
$0.14next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly226.6MTarget: Fund operations into 2028
Collaboration Revenue Quarterly8.2MTarget: Varies based on Gilead collaboration milestones
Watch Items
- Gilead Cost-Profit Share Opt-In DecisionTrigger: Receipt of Gilead's clinical development plan and budget for the HPI program (ABI-5366 and ABI-1179)Action: Evaluate and decide whether to opt into a 40% U.S. cost-profit share in lieu of milestones and royalties
- ABI-6250 Phase 2 InitiationTrigger: Q4 2026Action: Initiate Phase 2 clinical study for ABI-6250 in hepatitis delta virus (HDV)
- ABI-4334 Partnering StatusTrigger: Reclaiming full rights to the HBV programAction: Secure a strategic development partner for the next-generation capsid assembly modulator
Research as of 19 Jun 2026